Jul 29, 2010 by Brian Orelli, PhDThis FDA Panel Isn't BrilliantWhy doesn't Brilinta work in the U.S.? Who cares?
Jul 29, 2010 by Brian Orelli, PhDForget Respect -- Dendreon Needs Sales!Everyone knows the data already. Does publishing it really help?
Jul 29, 2010 by Brian Orelli, PhDBuy, Sell, or Hold: Biotech GenericsGeneric biotech drugs are coming. Hop on.
Jul 29, 2010 by Brian Orelli, PhDThis Best Biotech Is Cheaper Than You ThinkCelgene registers a monster quarter.
Jul 29, 2010 by Brian Orelli, PhDIs Abbott a Buy?It depends on management's ability to transition the company.
Jul 29, 2010 by Brian Orelli, PhDPipeline Checkup: Pfloundering PfizerPipelines are the key to growth.
Jul 28, 2010 by Brian Orelli, PhDFighting Hard to Keep a BlockbusterSanofi is suing the FDA. Did you expect something different?
Jul 28, 2010 by Brian Orelli, PhDNow There's an Illuminating IdeaHelping your customers sell more of your product makes a lot of sense.
Jul 28, 2010 by Brian Orelli, PhDAmplifying the Risk-Reward RatioMedtronic's latest gets a mixed reaction at advisory panel meeting.
Jul 27, 2010 by Brian Orelli, PhDBrilinta? I Think Not.AstraZeneca's new blood thinner is far from brilliant.
Jul 27, 2010 by Brian Orelli, PhDBranded? Generic? They're Both Doing Great!Teva registers strong growth on both fronts.
Jul 27, 2010 by Brian Orelli, PhDBetter Buy: Cell Therapeutics or Sequenom?Which one deserves your dollars more?
Jul 26, 2010 by Brian Orelli, PhDBeleaguered Biotech for Sale by Owner. Maybe.Will Genzyme's management sell before the turnaround is complete?
Jul 26, 2010 by Brian Orelli, PhDUp 20%! Guess That Hedge Wasn't NeededOnyx reports positive data for its recently acquired multiple myeloma drug.
Jul 23, 2010 by Brian Orelli, PhDBristol-Myers' Confusing Earnings Numbers ExplainedIt's the share count, baby.
Jul 23, 2010 by Brian Orelli, PhDEli Lilly Looks Great Today, but I'm Concerned About TomorrowEli Lilly is firing on all cylinders, but is there a blowout in its future?
Jul 22, 2010 by Brian Orelli, PhDIt's All About the Future for AmylinIts second quarter stank, but there's a lot up ahead.
Jul 22, 2010 by Brian Orelli, PhDA Sign of More Good Things to Come for AbbottIntegration savings should help margins down the line.
